NASH: Thiazolidinediones for NASHone pill doesn't fix everything

Nature Reviews Gastroenterology and Hepatology

Volumn 7, Issue 5, 2010, Pages 243-244

  Neuschwander Tetri, Brent A ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 6 PHOSPHOFRUCTOKINASE; GLITAZONE DERIVATIVE; GLUCOSE; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE;

ADIPOCYTE; ADIPOSE TISSUE; CLINICAL TRIAL; DIETARY INTAKE; DRUG MECHANISM; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIPOGENESIS; LIPOLYSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; TREATMENT DURATION; ANIMAL; BEHAVIOR THERAPY; DISEASE MODEL; FATTY LIVER; LIFESTYLE; LIVER TUMOR; METABOLISM; METHODOLOGY; MOUSE; NOTE; ORAL DRUG ADMINISTRATION; PROGNOSIS;

ADMINISTRATION, ORAL; ANIMALS; BEHAVIOR THERAPY; DISEASE MODELS, ANIMAL; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIFE STYLE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MICE; PROGNOSIS; THIAZOLIDINEDIONES;

EID: 77952034890     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2010.50     Document Type: Short Survey

References (12)

1. Clark, J. M. The epidemiology of nonalcoholic fatty liver disease in adults. J. Clin. Gastroenterol. 40, S5-S10 (2006).
2. Ratziu, V. et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLiRT 2) extension trial. Hepatology 51, 445-453 (2010).
3. Ratziu, V. et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver improvement with Rosiglitazone Therapy (FLiRT) Trial. Gastroenterology 135, 100-110 (2008).
4. Gastaldelli, A. et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 50, 1087-1093 (2009).
5. sanyal, A. J. et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120, 1183-1192 (2001).
6. Kintscher, U. & Law, R. E. PPARγ-mediated insulin sensitization: the importance of fat versus muscle. Am. J. Physiol. Endocrinol. Metab. 288, E287-E291 (2005).
7. Sugii, S. et al. PPARγ activation in adipocytes is sufficient for systemic insulin sensitization. Proc. Natl Acad. Sci. USA 106, 22504-22509 (2009).
8. Abdelmalek, M. F. et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology doi:10.1002/hep. 23535.
9. Kechagias, S. et al. Fast-food-based hyperalimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut 57, 649-654 (2008).
10. Tetri, H. H., Basaranoglu, M., Brunt, M. M., Yerian, L. M. & Neuschwander-Tetri, B. A. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G987-G995 (2008).
11. Collison, K. S. et al. Effect of dietary monosodium glutamate on trans fat-induced nonalcoholic fatty liver disease. J. Lipid Res. 50, 1521-1537 (2009).
12. Neuschwander-Tetri, B. A. Nontriglyceride hepatic lipotoxicity: the new paradigm for the pathogenesis of NASH. Curr. Gastroenterol. Rep. 12, 49-56 (2010).